Recruitment

Recruitment Status
Completed

Inclusion Criterias

Signed Informed consent
histologically proven prostate adenocarcinoma
Absence of metastases (lymph node or bone)
...
Signed Informed consent
histologically proven prostate adenocarcinoma
Absence of metastases (lymph node or bone)
One or more tumor nodules seen on MRI and PET Choline.
Indication of radiotherapy up to a total dose> 70 Gy and 2 Gy/day fractions
No concomitant hormonal treatment. (NB: the introduction of hormone therapy during radiotherapy before the second 18F-MISO is a criterion to study exit)
Social Insurance
Intermediate Risk : Gleason 7 and PSA (prostate specific antigen)<20 ng / ml, T <T2c or Gleason 6 and PSA 10-20 ng / ml, T <T2c

Exclusion Criterias

Age < 18 years old
Patient protected by law
Age < 18 years old
Patient protected by law

Summary

Conditions
Prostate Adenocarcinoma
Type
Interventional
Phase
Phase 2
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Diagnostic

Participation Requirements

Age
Between 18 years and 125 years
Gender
Only males

Inclusion Criterias

Signed Informed consent
histologically proven prostate adenocarcinoma
Absence of metastases (lymph node or bone)
...
Signed Informed consent
histologically proven prostate adenocarcinoma
Absence of metastases (lymph node or bone)
One or more tumor nodules seen on MRI and PET Choline.
Indication of radiotherapy up to a total dose> 70 Gy and 2 Gy/day fractions
No concomitant hormonal treatment. (NB: the introduction of hormone therapy during radiotherapy before the second 18F-MISO is a criterion to study exit)
Social Insurance
Intermediate Risk : Gleason 7 and PSA (prostate specific antigen)<20 ng / ml, T <T2c or Gleason 6 and PSA 10-20 ng / ml, T <T2c

Exclusion Criterias

Age < 18 years old
Patient protected by law
Age < 18 years old
Patient protected by law

Locations

St Herblain, 44805
Poitiers, 86000
St Herblain, 44805
Poitiers, 86000

Tracking Information

NCT #
NCT01898065
Collaborators
  • Poitiers University Hospital
  • IASON Gmbh, Feldkirchner strasse 4, 8054 Graz-Seiesberg AUSTRIA
  • Cyclopharma
Investigators
  • Principal Investigator: SUPIOT Stéphane, MD ICO René Gauducheau
  • SUPIOT Stéphane, MD ICO René Gauducheau